A year after adulterated heparin caused deaths in the United States and Europe, inspectors in California were still finding contaminated product in hospitals throughout the state, even though the manufacturer had sent out multiple recall notices, and the issue with the product was well known. As the pharmaceutical industry responds to regulatory mandates to address such weakness in the supply chain, it's important to ask, "Could this same thing happen in a 'serialized' world?"
The life of a product and part does not have to end when failure occurs, according to a new Aberdeen report entitled Best Practices in Return, Refurbishment and Repair 2012.
